ORG – Page 8 – Talk Bio

Tempest Seeks Strategic Partners to Launch Phase 3 Liver Cancer Trial Amid Funding Challenges

2 weeks ago talkbio0Tagged altretamine/cisplatin/cyclophosphamide protocol, amezalpat, Avastin, biotech, Clearance, Clinical Oncology, Liver and Intrahepatic Biliary Tract Carcinoma, partnerships, Peroxisome Proliferator-Activated Receptors, Phase 3 trial, strategic, Tecentriq, United States Food and Drug Administration

Tempest Therapeutics , Amezalpat , Phase 3 Trial , Liver Cancer (HCC) , Strategic Partnerships , Biotech Funding , PPAR⍺ Antagonist , Clinical Oncology , FDA Clearance , Tecentriq and Avastin Combination Therapy

Appeals Court Blocks Reinstatement of Fired Federal Probationary Workers, Affecting 20 Agencies

2 weeks ago talkbio0Tagged Administration occupational activities, Appeals court decision, Employee, federal, Federal reduction-in-force statute, firings, Supreme Court stay, Transplant Registry Unified Management Program, Worker

Federal probationary workers, Appeals court decision, Trump administration, Worker reinstatement halt, Federal reduction-in-force statute, Supreme Court stay, Probationary employee firings

The 5 Largest Biopharma Layoffs of Q1 2025: An Overview of Industry Restructuring

2 weeks ago talkbio0Tagged 2025, Biopharma layoffs, Drug Industry, Galapagos layoffs, Gilead, Industry, losses, Merck, Myers, Novartis, Q1 2025, restructuring, Squibb Layoffs, trends qualifier

Biopharma layoffs 2025, Novartis layoffs, Galapagos layoffs, Bristol Myers Squibb layoffs, Merck cuts, Gilead workforce reduction, Q1 2025 job cuts, biotech restructuring, pharmaceutical industry job losses, industry trends.

Novo Nordisk Invests $1.1 Billion to Expand GLP-1 Drug Manufacturing in Brazil

2 weeks ago talkbio0Tagged Brazil, Claros facility, Diabetes, Glucagon-Like Peptide 1, Investments, Montes, Nordisk, Obesity, Ozempic, pharmaceutical manufacturing, production, Wegovy

Novo Nordisk , GLP-1 production , Brazil investment , Wegovy and Ozempic , Diabetes treatment , Obesity treatment , Montes Claros facility , Pharmaceutical manufacturing

Annexon Advances Guillain-Barré Syndrome Awareness and Introduces Groundbreaking Targeted Therapy

2 weeks ago talkbio0Tagged Annexon, ANX005, Approved, GBS, Guillain-Barré syndrome, Move GBS Forward™, Phase 3, Phase 3 trial, Tanruprubart, Targeted Therapy, United States Food and Drug Administration

Guillain-Barré Syndrome (GBS) , Annexon , Tanruprubart (ANX005) , Targeted therapy , GBS education campaign , Move GBS Forward™ , Phase 3 trial results , FDA approval

Drug pricing watchdog ICER offers ways to increase obesity drug access

2 weeks ago talkbio0Tagged Access, drug price, ICER, Obesity, Policy, Wegovy

ICER, Obesity, Access, Wegovy, Policy, drug price

Former CBER head Peter Marks says he blocked RFK Jr. from vaccine safety database before leaving FDA: AP

2 weeks ago talkbio0Tagged Disease Outbreaks, Kennedy, Kennedy 's, Massive, Peter Marks, RFK Jr., United States Food and Drug Administration, Vaccine Safety, Vaccines, VAERS

Vaccines, Massive, Vaccine Safety, Kennedy, United States Food and Drug Administration, RFK Jr., Disease Outbreaks, Peter Marks, VAERS, Kennedy ‘s

: BMS’ Opdivo plus Yervoy snags FDA nod as first-line treatment for certain colorectal cancer patients

2 weeks ago talkbio0Tagged Approved, Burning Mouth Syndrome, Colorectal Carcinoma, Combined, first-line, United States Food and Drug Administration, Yervoy

United States Food and Drug Administration, Approved, Burning Mouth Syndrome, Colorectal Carcinoma, Yervoy, first-line, Combined

Descartes-08: Sustained Efficacy in Myasthenia Gravis as Cartesian Prepares for Phase III Trial

2 weeks ago talkbio0Tagged Autoimmune Diseases, Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes, CAR-T, Cartesian, Clinical Trials, gMG, mRNA-based, Myasthenia Gravis, Phase III AURORA trial

Descartes-08 , Myasthenia Gravis (gMG) , CAR-T therapy , Cartesian Therapeutics , mRNA-based treatment , Phase III AURORA trial , Autoimmune diseases , Clinical trial results

U.S. Congressional Report Calls for $15 Billion to Bolster Biotech Leadership Amid Rising Chinese Competition

2 weeks ago talkbio0Tagged Bioeconomy, Biomanufacturing Strategy, Biotech Competition, Biotechnology, Biotechnology Advantage, China, Investments, National Security Commission, Tech Rivalry, U.S.-China, United States

U.S. Biotechnology Advantage, China Biotech Competition, National Security Commission on Emerging Biotechnology, Biotechnology Investment, Biomanufacturing Strategy, U.S.-China Tech Rivalry, Bioeconomy